Fractional excretion of angiogenic factors in women with severe preeclampsia

Obstetrics and Gynecology

Volumn 107, Issue 5, 2006, Pages 1103-1113

  Buhimschi, Catalin S ^a   Magloire, Lissa ^a   Funai, Edmund ^a   Norwitz, Errol R ^a   Kuczynski, Edward ^a   Martin, Ryan ^a   Richman, Susan ^a   Guller, Seth ^a   Lockwood, Charles J ^a   Buhimschi, Irina A ^a  

^a YALE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALBUMIN; ANGIOGENIC FACTOR; CREATININE; PLACENTAL GROWTH FACTOR; VASCULOTROPIN; VASCULOTROPIN RECEPTOR 1;

ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE SEVERITY; FEMALE; HUMAN; PREECLAMPSIA; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN SECRETION; PROTEIN URINE LEVEL; PROTEINURIA;

ADULT; ALBUMINURIA; CASE-CONTROL STUDIES; CREATININE; FEMALE; HUMANS; PRE-ECLAMPSIA; PREGNANCY; PREGNANCY PROTEINS; SERUM ALBUMIN; SEVERITY OF ILLNESS INDEX; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-1;

EID: 33646779202     PISSN: 00297844     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.AOG.0000207698.74104.4f     Document Type: Article

References (32)

1. Wagner LK. Diagnosis and management of preeclampsia. Am Fam Physician 2004;70:2317-24.
2. Roberts JM, Cooper DW. Pathogenesis and genetics of preeclampsia. Lancet 2001;357:53-6.
3. Buhimschi IA, Saade GR, Chwalisz K, Garfield RE. The nitric oxide pathway in pre-eclampsia: pathophysiological implications. Hum Reprod Update 1998;4:25-42.
4. Ward K, Hata A, Jeunemaitre X, Helin C, Nelson L, Namikawa C, Farrington PF, et al. A molecular variant of angiotensinogen associated with preeclampsia. Nat Genet 1993;4:59.
5. Wallukat G, Homuth V, Fischer T, Horstkamp B, Jupner A, Baur E, et al. Patients with preeclampsia develop agonistic antibodies against the angiotensin AT 1 receptor. J Clin Invest 1999;103:945-52.
6. Fass MM, Schinling GA, Baller JFW, Visscher CA, Bakker WW. A new animal model for human preeclampsia: ultra-low dose of endotoxin infusion in pregnant rats. Am J Obstet Gynecol 1994;171:158-64.
7. Roberts JM, Redman CW. Preeclampsia: more than pregnancy induced hypertension. Lancet 1993;341:1447-51.
8. Maynard SE, Min JY, Merchan J, Lim KH, Li J, Mondai S, et al. Excess placental soluble fms-like tyrosine kinase 1 (sFlt1) may contribute to endothelial dysfunction, hypertension, and proteinuria in preeclampsia. J Clin Invest 2003;111:649-58.
9. Levine RJ, Maynard SE, Qian C, Lim KH, England LJ, Yu KF, et al. Circulating angiogenic factors and the risk of preeclampsia. N Engl J Med 2004;12;350:672-83.
10. Caron C, Goudemand J, Marey A, Beague D, Ducroux G, Drouvin F. Are haemostatic and fibrinolytic parameters predictors of preeclampsia in pregnancy-associated hypertension? Thromb Haemost 1991;66:410-14.
11. Spargo B, McCartney CP, Winemiller R. Glomerular capillary endotheliosis in toxemia of pregnancy. Arch Pathol 1959;68:593-9.
12. Zhou Y, McMaster M, Woo K, Janatpour M, Perry J, Karpanen T, et al. Vascular endothelial growth factor ligands and receptors that regulate human cytotrophoblast survival are dysregulated in severe preeclampsia and hemolysis, elevated liver enzymes, and low platelets syndrome. Am J Pathol 2002;160:1405-23.
13. Rodgers GM, Taylor RN, Roberts JM. Preeclampsia is associated with a serum factor cytotoxic to human endothelial cells. Am J Obstet Gynecol 1988;159:908-14.
14. Ahmed A, Dunk C, Ahmad S, Khaliq A. Regulation of placental vascular endothelial growth factor (VEGF) and placenta growth factor (PlGF) and soluble Flt-1 by oxygen- a review. Placenta 2000;21:S16-24.
15. Buhimschi CS, Norwitz ER, Funai E, Richman S, Guller S, Lockwood CJ, Buhimschi IA. Urinary angiogenic factors cluster hypertensive disorders and identify women with severe preeclampsia. Am J Obstet Gynecol 2005;192:734-41.
16. Levine RJ, Thadhani R, Qian C, Lam C, Lim K, Yu KF, et al. Urinary placental growth factor and risk of preeclampsia. JAMA 2005;293:77-85.
17. Diagnosis and management of preeclampsia and eclampsia. ACOG Practice Bulletin No. 33. American Collage of Obstetricians and Gynecologists. Obstet Gynecol 2002;99:159-67.
18. Rodriguez-Thompson D, Lieberman. Use of a random urinary protein to creatinine ratio for the diagnosis of significant proteinuria during pregnancy. Am J Obstet Gynecol 2001;185:808-11.
19. Hasslacher C. Clinical significance of microalbuminuria and evaluation of the Micral-Test. Clin Biochem 1993;26:283-7.
20. Shinagawa S, Saitoh M. A study on proteins contained in urine of gestosis patients. Biol Res Pregnancy Perinatol 1983;4:140-4.
21. Hayashi M, Ueda Y, Hoshimoto K, Ota Y, Fukasawa I, Sumori K, et al. Changes in urinary excretion of six biochemical parameters in normotensive pregnancy and preeclampsia. Am J Kidney Dis 2002;39:392-400.
22. Ashton SV, Whitley GS, Dash PR, Wareing M, Crocker IP, Baker PN, Cartwright. Uterine spiral artery remodeling involves endothelial apoptosis induced by extravillous trophoblast through Fas/FasL interactions. Arterioscler Thromb Vasc Biol 2005;25:102-8.
23. Torry DS, Hinrichs M, Torry RJ. Determinants of placental vascularity. Am J Reprod Immunol 2004;51:257-68.
24. Charnock-Jones DS, Sharkey AM, Boocock CA, Ahmed A, Plevin R, Ferrara N, et al. Localization and activation of the receptor for vascular endoteliat growth factor on human trophoblast and choriocarcinoma cells. Biol Reprod 1994;51:524-30.
25. Torry DS, Hinrichs M, Torry RJ. Determinants of placental vascularity. Am J Reprod Immunol 2004;51:257-68.
26. Sgambati E, Marini M, Thyrion GDZ, Parretti E, Mello G, Orlando C, et al. VEGF expression in the placenta from pregnancies complicated by hypertensive disorders. Br J Obstet Gynaecol 2004;111:564-70.
27. Simon M, Grone HJ, Johren O, et al. Expression of vascular endothelial growth factor and its receptors in human renal ontogenesis and in adult kidneys. Am J Physiol 1995;268:F240-50.
28. Schrijveres BF, Flyvbjerg A, De Vrise AS. The role of vascular endothelial growth factor (VEGF) in renal pathophysiology. Kidney Int 2004;65:2003-17.
29. Thomas S, Vanuystel J, Gruden G, Rodriguez V, Burt D, Gnudi L, et al. Vascular endothelial growth factor receptors in human mesangium in vitro and in glomerular disease. J Am Soc Nephrol 2000;11:1236-43.
30. Whittle C, Gillespie K, Harrison R, Mathieson PW, Harper SJ. Heterogeneous vascular endothelial growth factor (VEGF) isoform mRNA and receptor mRNA expression in humal glomeruli, and identification of VEGF1 48 mRNA, a novel truncated splice variant. Clin Sci 1999;97:303-12.
31. He Y, Smith SK, Day KA, Clark DE, Licence DR, Charnock-Jones SD. Alternative splicing of vascular endothelial growth factor (VEGF)-R1 (FLT-1) pre-mRNA is important for the regulation of VEGF activity. Mol Endocrinol 1999;13:537-45.
32. Roes EM, Steegers EA, Thomas CM, Geurts-Moespot A, Raijmakers MT, Peters WH, Sweep CG. High levels of urinary vascular endothelial growth factor in women with severe preeclampsia. Int J Biol Markers 2004;19:72-5.